Breaking News
Get 50% Off 0
🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% Off CLAIM SALE
Close

Evotec AG O.N. (1EVT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9.00 -0.17    -1.80%
12/07 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 123
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 9.00 - 9.00
Type:  Equity
Market:  Italy
ISIN:  DE0005664809 
Evotec AG 9.00 -0.17 -1.80%

Evotec AG Company Profile

 
Read the Evotec AG company profile to learn more about the business and the management team. View Evotec AG O.N. facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

5055

Equity Type

ORD

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Contact Information

Address Essener Bogen 7
Hamburg, 22419
Germany
Phone 49 40 560 81 0
Fax 49 40 560 81 222

Top Executives

Name Age Since Title
Iris Low-Friedrich 62 2014 Independent Chairperson of the Supervisory Board
Roland Sackers 56 2019 Independent Vice Chairperson of the Supervisory Board
Constanze Ulmer-Eilfort 61 2021 Independent Member of Supervisory Board
Elaine Sullivan 63 2015 Independent Member of Supervisory Board
Wesley Wheeler 59 2024 Independent Supervisory Board
Camilla Macapili Languille 41 2022 Member of the Supervisory Board
Sujata M. Bhavnani - 2024 Member of the Scientific Advisory Board
Manu Shankar Hari - 2024 Member of the Scientific Advisory Board
Marco Taglietti 64 2024 Chairman of the Scientific Advisory Board
T. Mark Miller - 2024 Member of the Scientific Advisory Board
Richard G. Wunderink - 2024 Member of the Scientific Advisory Board
Ruben Tommasi 58 2024 Member of the Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

EVTG Price Commentary

Write your thoughts about Evotec SE
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email